Innate Pharma (IPH) — Capital Reinvestment Ratio
Innate Pharma (IPH) has a Capital Reinvestment Ratio of 0.09x as of June 2024, meaning it reinvests 0% of its operating cash flow (€3.04 Million) in capital expenditures (€283.00K). Check Innate Pharma tangible equity quality to evaluate the tangible quality of the company's equity base.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Innate Pharma Capital Reinvestment Ratio (2006–2019)
This chart tracks Innate Pharma's Capital Reinvestment Ratio across 4 annual periods. For the full cash flow conversion analysis, see Innate Pharma operating cash flow efficiency.
Annual Capital Reinvestment Ratio for Innate Pharma (2006–2019)
Year-by-year Capital Reinvestment Ratio for Innate Pharma from 2006 to 2019. See Innate Pharma (IPH) free cash flow to measure how efficiently the company converts operating cash flow to free cash.
| Year | Reinvestment Ratio | Operating CF (EUR) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2019 | 1.87x | €34.92 Million | €65.40 Million | ▲ +5163.6% |
| 2015 | 0.04x | €207.91 Million | €7.40 Million | ▲ +43.5% |
| 2011 | 0.02x | €12.99 Million | €322.00K | ▼ -98.8% |
| 2006 | 2.09x | €360.00K | €752.00K | — |